Literature DB >> 33330751

Hepatocellular carcinoma with non-B and non-C hepatitis origin: epidemiology in Japan and surgical outcome.

Norihiro Kokudo1, Nobuyuki Takemura1, Tatsuya Kanto2, Ryosuke Tateishi3, Toru Igari4, Kiyoshi Hasegawa5.   

Abstract

During the last two decades, there has been a dramatic increase in so-called non-B non-C hepatocellular carcinoma (NBNC HCC) in Japan. Majority of NBNC HCC are considered as so-called metabolic HCC and some could be related to occult HBV infection. Although there have been some reports on histological features predominant in metabolic HCC, very few specific driver genes for NBNC HCC have been reported. Most of the NBNC HCC are found incidentally and are relatively large in size. Since liver function is generally normal or subnormal, such patients have a higher chance for undergoing curative surgery. Although there has been slightly conflicting long-term outcomes reported for NBNC HCC, slightly better outcomes may be expected compared to other etiologies after curative surgery. However, risk of recurrence depends on the background liver. NBNC HCC in cirrhotic patients have a persistently higher risk of tumor recurrence requiring a long-term postoperative surveillance. It would be safe to conclude at this moment that NBNC HCCs should be treated using the same surgical strategy as HCCs with viral origin, same operative indications and same follow-up protocol. 2019, National Center for Global Health and Medicine.

Entities:  

Keywords:  epidemiology; hepatitis; non-B non-C HCC; recurrence; surgical strategy

Year:  2019        PMID: 33330751      PMCID: PMC7731089          DOI: 10.35772/ghm.2019.01018

Source DB:  PubMed          Journal:  Glob Health Med        ISSN: 2434-9186


  34 in total

1.  Body mass index and adverse perioperative outcomes following hepatic resection.

Authors:  Amit K Mathur; Amir A Ghaferi; Nicholas H Osborne; Timothy M Pawlik; Darrell A Campbell; Michael J Englesbe; Theodore H Welling
Journal:  J Gastrointest Surg       Date:  2010-06-08       Impact factor: 3.452

2.  Effect of metabolic syndrome on perioperative outcomes after liver surgery: A National Surgical Quality Improvement Program (NSQIP) analysis.

Authors:  Neil H Bhayani; Omar Hyder; Wayne Frederick; Richard D Schulick; Christopher L Wolgang; Kenzo Hirose; Barish Edil; Joseph M Herman; Michael A Choti; Timothy M Pawlik
Journal:  Surgery       Date:  2012-08       Impact factor: 3.982

3.  Postoperative Outcomes for Patients with Non-B Non-C Hepatocellular Carcinoma: A Subgroup Analysis of Patients with a History of Hepatitis B Infection.

Authors:  Kiyohiko Omichi; Junichi Shindoh; Satoshi Yamamoto; Yutaka Matsuyama; Nobuhisa Akamatsu; Junichi Arita; Junichi Kaneko; Yoshihiro Sakamoto; Kiyoshi Hasegawa; Norihiro Kokudo
Journal:  Ann Surg Oncol       Date:  2015-09-08       Impact factor: 5.344

4.  Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score.

Authors:  Masatoshi Kudo; Hobyung Chung; Seiji Haji; Yukio Osaki; Hiroko Oka; Toshihito Seki; Hiroshi Kasugai; Yo Sasaki; Takashi Matsunaga
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

5.  Possible contribution of prior hepatitis B virus infection to the development of hepatocellular carcinoma.

Authors:  Hironori Tanaka; Yoshiaki Iwasaki; Kazuhiro Nouso; Yoshiyuki Kobayashi; Shin-Ichiro Nakamura; Eiji Matsumoto; Nobuyuki Toshikuni; Toshihiko Kaneyoshi; Toshiya Ohsawa; Kouichi Takaguchi; Kozo Fujio; Tomonori Senoh; Tohru Ohnishi; Kohsaku Sakaguchi; Yasushi Shiratori
Journal:  J Gastroenterol Hepatol       Date:  2005-06       Impact factor: 4.029

6.  Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study.

Authors:  Yuichiro Eguchi; Hideyuki Hyogo; Masafumi Ono; Toshihiko Mizuta; Naofumi Ono; Kazuma Fujimoto; Kazuaki Chayama; Toshiji Saibara
Journal:  J Gastroenterol       Date:  2012-02-11       Impact factor: 7.527

Review 7.  Gene signatures in the management of hepatocellular carcinoma.

Authors:  Yujin Hoshida; Agrin Moeini; Clara Alsinet; Kensuke Kojima; Augusto Villanueva
Journal:  Semin Oncol       Date:  2012-08       Impact factor: 4.929

8.  One thousand fifty-six hepatectomies without mortality in 8 years.

Authors:  Hiroshi Imamura; Yasuji Seyama; Norihiro Kokudo; Atsushi Maema; Yasuhiko Sugawara; Keiji Sano; Tadatoshi Takayama; Masatoshi Makuuchi
Journal:  Arch Surg       Date:  2003-11

9.  Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy.

Authors:  Winnie Yeo; Frankie K F Mo; Stephen L Chan; Nancy W Y Leung; Pun Hui; Wai-Yip Lam; Tony S K Mok; Kowk C Lam; Wing M Ho; Jane Koh; Julian W Tang; Anthony T Chan; Paul K S Chan
Journal:  Hepatology       Date:  2007-06       Impact factor: 17.425

10.  Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.

Authors:  Kornelius Schulze; Sandrine Imbeaud; Eric Letouzé; Ludmil B Alexandrov; Julien Calderaro; Sandra Rebouissou; Gabrielle Couchy; Clément Meiller; Jayendra Shinde; Frederic Soysouvanh; Anna-Line Calatayud; Roser Pinyol; Laura Pelletier; Charles Balabaud; Alexis Laurent; Jean-Frederic Blanc; Vincenzo Mazzaferro; Fabien Calvo; Augusto Villanueva; Jean-Charles Nault; Paulette Bioulac-Sage; Michael R Stratton; Josep M Llovet; Jessica Zucman-Rossi
Journal:  Nat Genet       Date:  2015-03-30       Impact factor: 38.330

View more
  2 in total

1.  Non-B, Non-C Hepatocellular Carcinoma in an HBV- and HCV-Endemic Area: A Community-Based Prospective Longitudinal Study.

Authors:  Te-Sheng Chang; Nien-Tzu Hsu; Shu-Chuan Chen; I-Lin Hsu; Mei-Hsuan Lee; Sheng-Nan Lu
Journal:  Viruses       Date:  2022-05-07       Impact factor: 5.818

2.  Intended preoperative trans-arterial embolization for large hepatocellular carcinoma: a retrospective cohort study.

Authors:  Ryo Saito; Hidetake Amemiya; Naohiro Hosomura; Hiromichi Kawaida; Katsutoshi Shoda; Shinji Furuya; Hidenori Akaike; Yoshihiko Kawaguchi; Shingo Inoue; Hiroshi Kono; Daisuke Ichikawa
Journal:  World J Surg Oncol       Date:  2022-03-22       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.